Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles from USA
Based on 7,633 articles published since 2008

These are the 7633 published articles about Parkinson Disease that originated from USA during 2008-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. 2015

Odin, P / Ray Chaudhuri, K / Slevin, J T / Volkmann, J / Dietrichs, E / Martinez-Martin, P / Krauss, J K / Henriksen, T / Katzenschlager, R / Antonini, A / Rascol, O / Poewe, W / Anonymous2260838. ·Department of Neurology, Lund University Hospital, 221 85 Lund, Sweden; Klinikum-Bremerhaven, D-27574 Bremerhaven, Germany. Electronic address: per.odin@med.lu.se. · King's College London, and National Parkinson Foundation Centre of Excellence, Dept of Neurology, King's College Hospital, London, UK. · Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 South Limestone Street, Lexington, KY 40536-0284, USA. · Department of Neurology, University Hospital of Würzburg, 97080 Würzburg, Germany. · Department of Neurology, Oslo University Hospital and University of Oslo, N-0424 Oslo, Norway. · National Center for Epidemiology and CIBERNED, ISCIII, Avenida Monforte de Lemos 5, 28029 Madrid, Spain. · Department of Neurosurgery, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. · University Hospital of Bispebjerg, Bispebjerg Bakke 23, 2400 København, NV, Denmark. · Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost - Donauspital, 1220 Wien Langobardenstraße 122, Austria. · Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. · Clinical Investigation Center 1436 and Department of Clinical Pharmacology, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France; Clinical Investigation Center 1436 and Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France. · Innsbruck Medical University/University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria. ·Parkinsonism Relat Disord · Pubmed #26233582.

ABSTRACT: Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of 13 movement disorder specialists. The ISC identified 71 clinical questions important for device-aided management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as 'critically important;' these were refined to 10 questions by the ISC to be addressed through available evidence and expert opinion. Draft guidance was presented at international/national meetings and revised based on feedback. Key take-home points are: • Patients requiring levodopa >5 times daily who have severe, troublesome 'off' periods (>1-2 h/day) despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for specialist assessment even if disease duration is <4 years. • Cognitive decline related to non-motor fluctuations is an indication for device-aided therapies. If cognitive impairment is mild, use deep brain stimulation (DBS) with caution. For patients who have cognitive impairment or dementia, intrajejunal levodopa infusion is considered as both therapeutic and palliative in some countries. Falls are linked to cognitive decline and are likely to become more frequent with device-aided therapies. • Insufficient control of motor complications (or drug-resistant tremor in the case of DBS) are indications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous apomorphine pump may be considered for patients aged >70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.

2 Guideline Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease. 2014

van der Marck, Marjolein A / Klok, Margit Ph C / Okun, Michael S / Giladi, Nir / Munneke, Marten / Bloem, Bastiaan R / Anonymous4170783. ·Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Department of Neurology, Nijmegen, The Netherlands. · University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, FL, USA. · Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. · Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Department of Neurology, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Scientific Institute for Quality of Healthcare, Nijmegen, The Netherlands. · Radboud university medical center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, The Netherlands. Electronic address: Bas.Bloem@radboudumc.nl. ·Parkinsonism Relat Disord · Pubmed #24484618.

ABSTRACT: Falls in Parkinson's disease (PD) are common and frequently devastating. Falls prevention is an urgent priority, but there is no accepted program that specifically addresses the risk profile in PD. Therefore, we aimed to provide consensus-based clinical practice recommendations that systematically address potential fall risk factors in PD. We developed an overview of both generic (age-related) and PD-specific factors. For each factor, we specified: best method of ascertainment; disciplines that should be involved in assessment and treatment; and which interventions could be engaged. Using a web-based tool, we asked 27 clinically active professionals from multiple relevant disciplines to evaluate this overview. The revised version was subsequently reviewed by 12 experts. Risk factors and their associated interventions were included in the final set of recommendations when at least 66% of reviewing experts agreed. These recommendations included 31 risk factors. Nearly all required a multidisciplinary team approach, usually involving a neurologist and PD-nurse specialist. Finally, the expert panel proposed to first identify the specific fall type and to tailor screening and treatment accordingly. A routine evaluation of all risk factors remains reserved for high-risk patients without prior falls, or for patients with seemingly unexplained falls. In conclusion, this project produced a set of consensus-based clinical practice recommendations for the examination and management of falls in PD. These may be used in two ways: for pragmatic use in current clinical practice, pending further evidence; and as the active intervention in clinical trials, aiming to evaluate the effectiveness and cost-effectiveness of large scale implementation.

3 Guideline Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. 2010

Zesiewicz, T A / Sullivan, K L / Arnulf, I / Chaudhuri, K R / Morgan, J C / Gronseth, G S / Miyasaki, J / Iverson, D J / Weiner, W J / Anonymous2020653. ·University of South Florida, Tampa, USA. ·Neurology · Pubmed #20231670.

ABSTRACT: OBJECTIVE: Nonmotor symptoms (sleep dysfunction, sensory symptoms, autonomic dysfunction, mood disorders, and cognitive abnormalities) in Parkinson disease (PD) are a major cause of morbidity, yet are often underrecognized. This evidence-based practice parameter evaluates treatment options for the nonmotor symptoms of PD. Articles pertaining to cognitive and mood dysfunction in PD, as well as treatment of sialorrhea with botulinum toxin, were previously reviewed as part of American Academy of Neurology practice parameters and were not included here. METHODS: A literature search of MEDLINE, EMBASE, and Science Citation Index was performed to identify clinical trials in patients with nonmotor symptoms of PD published between 1966 and August 2008. Articles were classified according to a 4-tiered level of evidence scheme and recommendations were based on the level of evidence. RESULTS AND RECOMMENDATIONS: Sildenafil citrate (50 mg) may be considered to treat erectile dysfunction in patients with Parkinson disease (PD) (Level C). Macrogol (polyethylene glycol) may be considered to treat constipation in patients with PD (Level C). The use of levodopa/carbidopa probably decreases the frequency of spontaneous nighttime leg movements, and should be considered to treat periodic limb movements of sleep in patients with PD (Level B). There is insufficient evidence to support or refute specific treatments for urinary incontinence, orthostatic hypotension, and anxiety (Level U). Future research should include concerted and interdisciplinary efforts toward finding treatments for nonmotor symptoms of PD.

4 Guideline Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. 2008

Thurman, David J / Stevens, Judy A / Rao, Jaya K / Anonymous6930591. ·National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. ·Neurology · Pubmed #18250292.

ABSTRACT: OBJECTIVE: To develop a practice parameter for screening methods and assessments of risk for falls pertaining to patients likely to be seen in neurology practices. METHODS: Relevant literature was systematically reviewed and strength of evidence classified based on the American Academy of Neurology's criteria (Level A: established; Level B: probable; Level C: possible). RESULTS: An increased risk of falls is established among persons with diagnoses of stroke, dementia, and disorders of gait and balance (Level A) and probable among patients with Parkinson disease, peripheral neuropathy, lower extremity weakness or sensory loss, and substantial vision loss (Level B). A history of falling in the past year strongly predicts the likelihood of future falls (Level A). Screening measures have been developed to further assess risks of falls, including functional assessments that may be useful (Levels B and C). Several of these assess overlapping neurologic functions--i.e., gait, mobility, and balance--and there is insufficient evidence to assess whether they offer benefit beyond that provided by a standard neurologic examination. CONCLUSIONS: Patients with neurologic or general conditions associated with an increased risk of falling should be asked about recent falls and further examined for the presence of specific neurologic deficits that predict falls, which include gait and balance disorders; deficits of lower extremity strength, sensation, and coordination; and cognitive impairments. If substantial risks of falls are identified, appropriate interventions that are described in other evidence-based guidelines may be considered.

5 Editorial When to Start Levodopa Therapy for Parkinson's Disease. 2019

Bressman, Susan / Saunders-Pullman, Rachel. ·From the Icahn School of Medicine at Mt. Sinai, New York. ·N Engl J Med · Pubmed #30673551.

ABSTRACT: -- No abstract --

6 Editorial Enabling biomarker discovery in Parkinson's disease using multiomics: challenges, promise and the future. 2019

Kiebish, Michael A / Narain, Niven R. ·BERG LLC, Precision Medicine Division, Framingham, MA 01701, USA. ·Per Med · Pubmed #30422077.

ABSTRACT: -- No abstract --

7 Editorial DBS and Impulse Control Disorders in PD: I think we got this…..wait! we don't. 2018

Mehta, Shyamal H. ·Mayo Clinic College of Medicine, Mayo Clinic Arizona, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, United States. Electronic address: mehta.shyamal@mayo.edu. ·Parkinsonism Relat Disord · Pubmed #30558856.

ABSTRACT: -- No abstract --

8 Editorial Managing anxiety in Parkinson's disease: the role of nonpharmacological strategies. 2018

Rocha, Natalia P / Teixeira, Antonio L. ·Universidade Federal de Minas Gerais, Faculdade de Medicina, Laboratório Interdisciplinar de Investigação Médica, Belo Horizonte MG, Brasil. · The University of Texas Health Science Center at Houston, McGovern Medical School, Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, Houston, Texas, USA. ·Arq Neuropsiquiatr · Pubmed #30231120.

ABSTRACT: -- No abstract --

9 Editorial Mendel and urate: Acid test or random noise? 2018

Brown, Ethan G / Goldman, Samuel M / Tanner, Caroline M. ·Department of Neurology, University of California - San Francisco, San Francisco, CA, USA; Department of Neurology, Weil Institute for Neurosciences, University of California - San Francisco, San Francisco, CA, USA. · Department of Neurology, University of California - San Francisco, San Francisco, CA, USA; Division of Occupational and Environmental Medicine, University of California - San Francisco, San Francisco, CA, USA; Medical Service, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA. · Department of Neurology, University of California - San Francisco, San Francisco, CA, USA; Department of Neurology, Weil Institute for Neurosciences, University of California - San Francisco, San Francisco, CA, USA; Parkinson's Disease Research, Education and Clinical Center, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA. Electronic address: Caroline.tanner@ucsf.edu. ·Parkinsonism Relat Disord · Pubmed #30100365.

ABSTRACT: -- No abstract --

10 Editorial Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones? 2018

Hölscher, Christian / De Felice, Fernanda G / Greig, Nigel H / Ferreira, Sergio T. ·Biomedical and Life Sciences, Lancaster University, Lancaster, UK. Electronic address: c.holscher@lancaster.ac.uk. · Centre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. · Drug Design & Development Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, USA. · Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. ·Neuropharmacology · Pubmed #29782874.

ABSTRACT: -- No abstract --

11 Editorial RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape. 2018

Dowdy, Steven F / Levy, Matthew. ·1 Department of Cellular and Molecular Medicine, University of California San Diego (UCSD) School of Medicine , La Jolla, California. · 2 Vitrisa Therapeutics, Inc. , Durham, North Carolina. ·Nucleic Acid Ther · Pubmed #29782220.

ABSTRACT: -- No abstract --

12 Editorial Cerebrospinal fluid levels of alpha-synuclein in PARKINSON'S disease: Another long and winding road. 2018

Markopoulou, Katerina / Compta, Yaroslau. ·Movement Disorders Section, Department of Neurology, NorthShore University HealthSystem, Chicago, Evanston, USA; University of Chicago, Pritzker School of Medicine, Chicago, IL, USA. · Parkinson's Disease and Movement Disorders Unit, Neurology Service, ICN, Hospital Clínic, IDIBAPS, CIBERNED, Barcelona, Catalonia, Spain; Physiology Unit, Department of Biomedicine, Institut de Neurociències, University of Barcelona, Barcelona, Catalonia, Spain. Electronic address: ycompta@clinic.cat. ·Parkinsonism Relat Disord · Pubmed #29548634.

ABSTRACT: -- No abstract --

13 Editorial Take care to identify apathy in idiopathic rapid eye movement sleep behavior disorder. 2018

St Louis, E K. ·Mayo Center for Sleep Medicine, Departments of Neurology and Medicine, Mayo Clinic and Foundation, Rochester, MN, USA. ·Eur J Neurol · Pubmed #29528541.

ABSTRACT: -- No abstract --

14 Editorial Neurotherapeutics: Recent Developments. 2018

Rizvi, Syed. ·Associate Professor of Clinical Neurosciences, Alpert Medical School of Brown University; Director, Rhode Island Hospital Multiple Sclerosis Center; Director, Neurology Outpatient Center. ·R I Med J (2013) · Pubmed #29490320.

ABSTRACT: -- No abstract --

15 Editorial MCI in Parkinson's disease. 2018

Friedman, Joseph H. ·Dept. of Neurology, Butler Hospital, 345 Blackstone Blvd, Providence, RI 02906, USA; Dept. of Neurology, Warren Alpert Medical School of Brown University, Providence, RI 02906, USA. Electronic address: Joseph_friedman@brown.edu. ·Parkinsonism Relat Disord · Pubmed #29413123.

ABSTRACT: -- No abstract --

16 Editorial Immunologic treatment of Parkinson's disease. 2018

Jankovic, Joseph. ·Distinguished Chair in Movement Disorders, Director, Parkinson's Disease Center & Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A; Houston, TX 77030-4202, USA. ·Immunotherapy · Pubmed #29260621.

ABSTRACT: -- No abstract --

17 Editorial The future burden of Parkinson's disease. 2018

Rocca, Walter A. ·Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. · Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. ·Mov Disord · Pubmed #28782890.

ABSTRACT: -- No abstract --

18 Editorial Translating scientific advances into disease-modifying therapies for Parkinson's Disease. 2017

Cenci, M Angela / Olanow, C Warren. ·Basal Ganglia Pathophysiology Unit, Dept. Exp. Med. Science, Lund University, Lund (Sweden). · Clintrex LLC; Department of Neurology and Department of Neurosciences, Mount Sinai School of Medicine, New York. ·Exp Neurol · Pubmed #29145992.

ABSTRACT: -- No abstract --

19 Editorial Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years? 2017

Goetz, Christopher G. ·Rush University Medical Center, Chicago, Illinois, USA. ·Mov Disord · Pubmed #29119602.

ABSTRACT: -- No abstract --

20 Editorial What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease. 2017

Standaert, David G. ·Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. ·Mov Disord · Pubmed #29068500.

ABSTRACT: -- No abstract --

21 Editorial Dietary antioxidants and Parkinson's disease. 2017

Ascherio, Alberto / Schwarzschild, Michael A. ·Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. · Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA. · Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. · Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. ·Mov Disord · Pubmed #28976040.

ABSTRACT: -- No abstract --

22 Editorial Can lifestyle modification slow progression of Parkinson disease? 2017

Hedera, Peter / Davis, Thomas L. ·From the Department of Neurology, Vanderbilt University Medical Center, Nashville, TN. peter.hedera@vanderbilt.edu. · From the Department of Neurology, Vanderbilt University Medical Center, Nashville, TN. ·Neurology · Pubmed #28972193.

ABSTRACT: -- No abstract --

23 Editorial Virtually reducing fall risk in Parkinson disease. 2017

Moreau, Caroline / Barton, Brandon R / Devos, David. ·From the Service de Neurologie (C.M., D.D.) and Services de Pharmacologie and Médicale (D.D.), LICEND COEN Center, Université de Lille, CHU de Lille, INSERM UMRS_1171, France · Department of Neurological Sciences (B.R.B.), Rush University Medical Center · and Neurology Service (B.R.B.), Jesse Brown VA Medical Center, Chicago, IL. ·Neurology · Pubmed #28954881.

ABSTRACT: -- No abstract --

24 Editorial Biomarkers for early detection of Parkinson disease: A scent of consistency with olfactory dysfunction. 2017

Bowman, Gene L. ·From the Department of Nutrition and Brain Health, Nestlé Institute of Health Sciences, Lausanne, Switzerland; and the Brain Institute, Department of Neurology, Oregon Health & Science University, Portland. gene.bowman@rd.nestle.com. ·Neurology · Pubmed #28878052.

ABSTRACT: -- No abstract --

25 Editorial Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection. 2017

Labrie, Viviane / Brundin, Patrik. ·Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, USA. ·J Innate Immun · Pubmed #28866688.

ABSTRACT: Intraneuronal accumulation of misfolded alpha-synuclein in the central and peripheral nervous systems is strongly linked to Parkinson disease (PD) and other related synucleinopathies. In rare inherited forms of PD, point mutations or gene multiplications mediate the formation of alpha-synuclein protein aggregates. However, in most PD cases it is presumed that the combined effects of ageing and environmental factors drive the formation of alpha-synuclein aggregates. Despite advances regarding alpha-synuclein pathobiology, the normal functions of this protein and factors that regulate its expression are not well understood. We discuss a recent study reporting that viral infection induces alpha-synuclein expression in neurons of the gastrointestinal tract. Alpha-synuclein levels increased during norovirus infection in the duodenum of children. In an in vitro paradigm, monomeric and oligomeric alpha-synuclein acted as chemoattractants for neutrophils and monocytes, and promoted the maturation of dendritic cells. This suggests that alpha-synuclein facilitates immune responses to infection. We explore the possibility that intestinal infections, and associated inflammation, place individuals at increased risk of PD by increasing alpha-synuclein levels and promoting the formation of alpha-synuclein aggregates that propagate in a prion-like fashion via the vagal nerve to the brainstem.